Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thad C. Hagen is active.

Publication


Featured researches published by Thad C. Hagen.


Neuroendocrinology | 1980

Age-Related Changes in Central Nervous System Beta-Endorphin and ACTH

S.R. Gambert; Thomas L. Garthwaite; C.H. Pontzer; Thad C. Hagen

Aging is associated with alterations in mood, thermoregulation, pain threshold, and stress response. Because these functions may be modulated by endogenous opiates, we measured immunoreactive ACTH with beta-endorphin in discrete brain areas and pituitary glands from rats aged 6 weeks (young), 6 months (mature), and 20-24 months (senscent). Beta-Endorphin and ACTH declined significantly with aging in the hypothalamus and corpus striatum. Beta-Endorphin and ACTH increased in the frontal lobe during early life; however, no change was noted after maturity. A discordant response with age was noted in the pituitary in that (ACTH did not change, while beta-endorphin increased early in life without change after maturity. Cerebellar tissue exhibited no immunoreactive ACTH or beta-endorphin. Age-related changes in brain and pituitary beta-endorphin and ACTH must be considered in the evaluation of the physiological aging process and when comparing studies of these neuropeptides.


Neuroendocrinology | 1986

Antisera to Vasoactive Intestinal Polypeptide Inhibit Basal Prolactin Release from Dispersed Anterior Pituitary Cells

Thad C. Hagen; Mohammed A. Arnaout; Wendy J. Scherzer; Donald R. Martinson; Thomas L. Garthwaite

Vasoactive intestinal polypeptide (VIP) has been identified in hypothalamic tissue, is secreted into hypophysial portal blood, and stimulates prolactin (PRL) release in vivo and in vitro. It has been proposed, therefore, that VIP is a physiologic PRL-releasing factor. In this study, we confirm that VIP stimulates PRL release from rat pituitary cells in vitro, and demonstrate that an anti-VIP antiserum blocks VIP-induced PRL secretion. Surprisingly, the anti-VIP antiserum inhibited basal PRL secretion from rat pituitary cells in 3 separate experiments. Data from these experiments were pooled, as the responses were similar, revealing basal PRL release of 10.7 +/- 1.3 ng rPRL/10(5) cells (X +/- SE), while anti-VIP antisera significantly inhibited release to 4.4 +/- 0.6 ng rPRL/10(5) cells (p less than 0.001). PRL release in incubates containing control non-immune sera did not differ from basal release, 8.1 ng rPRL/10(5) cells. A further control experiment was conducted wherein cells were incubated with an anti-ACTH antiserum, representing another hyperimmune serum, which had no effect on PRL secretion. These data suggest that VIP, in addition to its possible role as a hypothalamic-derived PRL-releasing factor, may play a role within the pituitary as a regulator of basal PRL secretion.


Experimental Biology and Medicine | 1981

Running Elevates Plasma β-Endorphin Immunoreactivity and ACTH in Untrained Human Subjects

Steven R. Gambert; Thomas L. Garthwaite; Carol H. Pontzer; Elizabeth E. Cook; Felix E. Tristani; Edmund H. Duthie; Donald R. Martinson; Thad C. Hagen; Daniel J. McCarty

Abstract Twenty minutes of submaximal treadmill running was associated with an elevation in plasma levels of β-endorphin immunoreactivity (P < 0.02). This increase was greater in men (14.9 ± 3.4 fmole/ml) than women (2.6 ± 1.2 fmole/ml) (P < 0.05). Plasma levels of ACTH and growth hormone also increased after running. ACTH increased more in men (7.8 ± 1.1 fmole/ml) than in women (1.1 ± 0.44 fmole/ml) (P < 0.02). There was a similar growth hormone response in both sexes. No correlation can at this time be made with levels in the central nervous system. Changes in plasma levels of β-endorphin immunoreactivity may be responsible for some of the euphoria and analgesia anecdotally associated with running.


Neuroendocrinology | 1979

Evidence that Serotonin Stimulates a Prolactin-Releasing Factor in the Rat

Thomas L. Garthwaite; Thad C. Hagen

Methanol extracts of rat plasma resulted in release of prolactin (PRL) from rat hemipituitaries in vitro with a linear log-dose relationship. This prolactin-releasing factor (PRF)-like activity was not altered in plasma from rats treated with bromocryptine or chlorpromazine despite significant suppression and stimulation of plasma PRL levels, respectively. Fluoxetine, a serotonin reuptake inhibitor, plus 5-hydroxytryptophan, the immediate precursor of serotonin, markedly stimulated both plasma PRL and plasma PRF-like activity. Neither fluoxetine, 5-hydroxytryptophan, nor the combination directly stimulated PRL release from rat pituitary tissue in vitro. We conclude that serotonergic stimulation augments PRL release via a PRF.


The New England Journal of Medicine | 1984

Inappropriate secretion of antidiuretic hormone after transsphenoidal surgery for pituitary tumors.

Joseph F. Cusick; Thad C. Hagen; James W. Kindling

THE syndrome of inappropriate secretion of antidiuretic hormone (ADH) has been noted in association with a variety of neurologic disorders,1 2 3 but its occurrence as a transient complication of pi...


Neuroendocrinology | 1986

Hypothalamic prolactin: characterization by radioimmunoassay and bioassay and response to hypophysectomy and restraint stress.

Nicholas V. Emanuele; Lisa Metcalfe; Lynn Wallock; John Tentler; Thad C. Hagen; Charles T. Beer; Donald R. Martinson; Peter W. Gout; Lidia Kirsteins; A. M. Lawrence

Prompted by immunohistochemical reports of prolactin-like immunoreactivity in cell bodies within the rat hypothalamus, a study was undertaken to quantitate the immunologic and biologic activity of this material. Hypothalamic concentrations of prolactin-like immunoreactivity averaged 402 +/- 23 pg/mg of protein (n = 30). 97% recovery of rat prolactin standards added to homogenates of hypothalamus insured that neuronal tissue, as prepared for these studies, did not interfere with the radioimmunoassay of rat prolactin. Examination of the elution profile from Sephadex G-75 columns of the prolactin-like immunoreactivity in hypothalamic extracts showed that the majority of hypothalamic prolactin-like substance was of a larger molecular size than pituitary prolactin. While increasing amounts of brain extract progressively displaced more I125 prolactin from antibody-binding sites, the displacement curve produced by adding hypothalamic extract was not parallel to that produced by the addition of increasing amounts of anterior pituitary prolactin standards of rat origin. Hypothalamic extracts from hypophysectomized animals, analyzed for biologic activity in the Nb2 lymphoma cell assay, revealed prolactin-like bioactivity, but the bioactivity/immunoactivity (B/I) ratios for hypothalamic extracts were significantly lower than the B/I ratios for pituitary prolactin (0.71 +/- 0.04 for pituitary, vs. 0.19 +/- 0.06 in the hypothalamus; p less than 0.001). Hypophysectomy, which led to the expected fall in serum prolactin to undetectable levels, and restraint stress, which resulted in a statistically significant 4-fold rise in serum prolactin, caused no change in prolactin concentrations in the hypothalamus, indicating that brain prolactin-like substance is regulated independently of pituitary prolactin and circulating serum prolactin levels.


Brain Research | 1987

Extrahypothalamic brain prolactin: characterization and evidence for independence from pituitary prolactin

Nicholas V. Emanuele; Lisa Metcalfe; Lynn Walloch; John Tentler; Thad C. Hagen; Charles T. Beer; Donald R. Martinson; Peter W. Gout; Lidia Kirsteins; A.M. Lawrence

Prompted by reports of immunohistochemical localization of a prolactin-like immunoreactivity (PLI) within the rat brain, a study was undertaken to define the immunologic and biologic characteristics of this material in extrahypothalamic regions of the rat brain. Ninety-seven percent recovery of rat prolactin standard, added to homogenates of brain parts, insured that neuronal tissue did not interfere with the radioimmunoassay for rat prolactin. PLI was consistently found in the cerebellum, thalamus, brainstem (pons-medulla), hippocampus, cerebral cortex and caudate. Examination of the elution profile of each of the extrahypothalamic brain parts from Sephadex G-75 columns showed that, although a small amount of brain PLI elutes in the vicinity of the anterior pituitary prolactin marker, the bulk of brain-based PLI migrates with the void volume and as late eluting, low molecular weight material. While increasing amounts of brain extracts progressively displaced more 125I-prolactin from antibody binding, the displacement curve was not parallel to that produced by the addition of increasing amounts of anterior pituitary prolactin standards of rat origin. Extracts of various brain parts from hypophysectomized animals, analyzed for biologic activity in the Nb2 lymphoma cell assay, revealed prolactin-like bioactivity, but the bioactivity/immunoreactivity ratio for some of the brain parts was significantly lower than that for pituitary prolactin. Hypophysectomy, which led to the expected fall in serum prolactin to undetectable levels, and restraint stress, which resulted in a statistically significant 4-fold rise in serum prolactin, caused no change in prolactin concentrations in extrahypothalamic brain parts, indicating that brain PLI is regulated independently of pituitary prolactin and of circulating serum prolactin levels.


Pharmacology, Biochemistry and Behavior | 1984

The effects of δ9-tetrahydrocannabinol on serum thyrotropin levels in the rat

Cecilia J. Hillard; Neil E. Farber; Thad C. Hagen; Alan S. Bloom

The effects of acute treatment with delta 9-tetrahydrocannabinol (delta 9-THC) on serum levels of thyrotropin (TSH) and the thyroid hormones triiodothyronine (T3) and thyroxine (T4) were determined in the rat. Intraperitoneal doses of delta 9-THC greater than 3 mg/kg reduced serum TSH levels to less than 10% of control. The ED50 for delta 9-THC was approximately 0.3 mg/kg. After a 10 mg/kg dose of delta 9-THC, the maximum decrease in serum TSH occurred at one hour. Both serum T3 and serum T4 levels were decreased by a single 10 mg/kg delta 9-THC injection with maximal decreases at 6 hr post-injection. The effects of delta 9-THC on the ability of thyrotropin releasing hormone (TRH) to increase serum TSH and T3 were determined. TRH produced a 10-fold increase in serum TSH levels and this increase was unaffected by delta 9-THC pretreatment. Serum T3 levels were slightly increased by TRH and this increase was also unaffected by delta 9-THC. These findings indicate that acute treatment with delta 9-THC results in a decrease in circulating TSH, T3 and T4 levels but has no effect on the pituitary or thyroid response to exogenous TRH.


Neurosurgery | 1980

Radiological assessment of intrasellar prolactin-secreting tumors.

Joseph F. Cusick; Victor M. Haughton; Thad C. Hagen

In this study, the value of high resolution computed tomography (CT) in defining prolactin-secreting intrasellar tumors was compared to the value of conventional hypocycloidal polytomography. In all cases, contrast-enhanced coronal CT images were capable of defining these tumors by the demonstration of abnormal dimensions, upward convexity, or regional low density areas in the pituitary gland. The focal regions of decreased density and contrast enhancement correlated consistently with the prolactin-secreting microadenoma location found during surgical removal. Polytomography was not as effective as CT in the diagnostic differentiation of these adenomas.


Diabetes | 1975

Effect of glucose on the growth hormone response to L-dopa in normal and diabetic subjects.

Kamel Ajlouni; Donald R. Martinson; Thad C. Hagen

The effect of hyperglycemia on the growth hormone response to oral L-dopa (500 mg.) was assessed in eight normal and eight insulin-dependent diabetic subjects. A peak growth hormone response of 21.0 ±4.0 ng./ml. (mean / S.E.M.), significantly above baseline (p <0.01), was achieved in the normal group following oral L-dopa. Glucose concentrations did not change and were approximately 80 mg./100 ml. throughout. Administration of 100 gm. oral glucose with the L-dopa, or thirty minutes thereafter, totally suppressed the growth hormone response in all eight and six of the subjects, respectively. A peak growth hormone response of 20.0 /1.7 ng./ml. (mean / S.E.M.), significantly above baseline (p <0.001), was obtained in eight nonobese, insulin-dependent diabetics, in spite of prevailing hyperglycemia (mean plasma glucose 243-258 mg./100 ml.) throughout the test. Endogenous hyperglycemia was achieved in these patients by lessening the usual strict adherence to plasma glucose control for the purpose of the study. These results suggest an abnormality in the hypothalamus or pituitary of diabetic subjects allowing growth hormone responsiveness in spite of hyperglycemia.

Collaboration


Dive into the Thad C. Hagen's collaboration.

Top Co-Authors

Avatar

Thomas L. Garthwaite

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Donald R. Martinson

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Mohammed A. Arnaout

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Kamel Ajlouni

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

A. M. Lawrence

Loyola University Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carol H. Pontzer

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Diana Maas

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Joseph F. Cusick

Medical College of Wisconsin

View shared research outputs
Researchain Logo
Decentralizing Knowledge